Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070843 | 0.85 | MEN1 (0.33) | TDP1MEN1KMT2A | |
| SCHEMBL5544690 | 0.84 | MEN1 (0.42) | MEN1KMT2A | |
| SCHEMBL1746 | 0.84 | — | — | |
| SCHEMBL7097725 | 0.84 | — | — | |
| SCHEMBL4912357 | 0.81 | MEN1 (0.43) | MEN1KMT2A | |
| Cyclohexane SCHEMBL6934253 | 0.81 | MEN1 (0.43) | MEN1KMT2A | |
| Fluoride SCHEMBL73855 | 0.81 | MEN1 (0.40) | MEN1KMT2A | |
| Fluoride SCHEMBL1025917 | 0.81 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL3210291 | 0.81 | MEN1 (0.40) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL22577541 | 0.81 | MEN1 (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148355-B2 | Process for the preparation of repaglinide | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-12 | — | — | US | claimed |
| EP-1432682-B1 | PROCESS FOR THE PREPARATION OF REPAGLINIDE | RANBAXY LAB LTD (IN) | 2005-05-25 | — | — | EP | claimed |
| US-20050107614-A1 | Process for the preparation of repaglinide | RANBAXY LABORATORIES LIMITED (IN) | 2005-05-19 | — | — | US | claimed |
| US-20130274284-A1 | PREPARATION OF PRASUGREL HYDROCHLORIDE | DR. REDDY'S LABORATORIES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481729-B2 | Processes for the preparation of paliperidone | MSN LABORATORIES LIMITED (IN) | 2013-07-09 | — | — | US | disclosed |
| EP-2601200-A2 | PREPARATION OF PRASUGREL HYDROCHLORIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012018791-A2 | PREPARATION OF PRASUGREL HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-02-09 | — | — | WO | disclosed |
| US-20110293889-A1 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | US | disclosed |
| US-8058438-B2 | Eszopiclone process | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-11-15 | — | — | US | disclosed |
| US-20090099359-A1 | ESZOPICLONE PROCESS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-04-16 | — | — | US | disclosed |
| US-7476737-B2 | Reacting 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]-pyrazine with 1-chlorocarbonyl-4-methylpiperazine hydrochloride to form zopiclone, reacting zopiclone with an enantiomerically pure di-p-toluoyl tartaric acid, and recovering a solid salt, insomnia | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-01-13 | — | — | US | disclosed |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | OKUMURA YOSHIYUKI (JP) | 2003-01-16 | — | — | US | disclosed |
| US-6476042-B1 | Combination therapy for the treatment of migraine | PFIZER INC. | 2002-11-05 | — | — | US | disclosed |
| EP-0937722-B1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6310079-B1 | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2001-10-30 | — | — | US | disclosed |
| EP-1064965-A2 | Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1064966-A2 | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1051995-A2 | 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| EP-0937722-A1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0846689-A1 | Benzimidazole compounds | PFIZER INC. (US) | 1998-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274284-A1 | PREPARATION OF PRASUGREL HYDROCHLORIDE | PFKP, PF4, PTAFR | TDP1 3209/4885MEN1 2691/4885KMT2A 3884/4885 |
| US-20050107614-A1 | Process for the preparation of repaglinide | GCG, GCGR, GID4 | TDP1 2700/4885MEN1 2867/4885KMT2A 2777/4885 |
| US-20090099359-A1 | ESZOPICLONE PROCESS | GRIK5, EML4, CYP3A5 | TDP1 2904/4885MEN1 4562/4885KMT2A 266/4885 |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | PTGS1, CBR1, CBR3 | TDP1 3893/4885MEN1 4840/4885KMT2A 1611/4885 |
| US-20110293889-A1 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | AVPR2, AVPR1B, AVPR1A | TDP1 3779/4885MEN1 2577/4885KMT2A 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.